A denial letter is not the end. Understand why insurers say no, file the appeal that wins, and use compounded GLP-1 to bridge the gap while the paperwork moves.
GLP-1 medications are among the most-denied prescription drugs in America. Wegovy and Zepbound — explicitly approved for weight management — are excluded from roughly half of employer plans. Even Ozempic and Mounjaro, approved for type 2 diabetes, face heavy prior-authorisation gates. Five denial patterns account for the vast majority:
Most plans require BMI ≥30, or ≥27 with comorbidity (hypertension, dyslipidemia, sleep apnea). BMI 26.9 = automatic denial.
Many plans cover Ozempic/Mounjaro for type 2 diabetes only and exclude weight-management indications (Wegovy/Zepbound) entirely.
PA forms require documented BMI trajectory, prior diet/exercise attempts, and sometimes prior weight-loss-drug trials. Missing fields = denial.
Plan requires you fail phentermine, contrave, or older agents first. Skipping = denial.
Roughly half of US employer plans exclude obesity medications as a category. No appeal will succeed.
Call member services and request the EOB and the specific denial code. Without the written reason, you cannot appeal effectively.
A strong LMN cites your BMI, weight history, comorbidities, prior weight-loss attempts (with dates/outcomes), and ICD-10 codes (E66.01 obesity, E11.9 T2DM if applicable).
Submit the LMN, your medical records, and a cover letter referencing the denial code. Most plans answer internal appeals within 30 days; expedited within 72 hours if urgent.
Under the ACA, you have the right to an Independent Review Organisation (IRO) appeal — an outside medical reviewer with no financial stake in the outcome. ~50% of external appeals succeed.
Appeals take 30–90 days. Compounded semaglutide ($200–400/mo cash) lets you continue therapy without losing momentum while you fight the denial.
Appeals take 30–120 days. Stopping GLP-1 therapy mid-titration causes weight regain and metabolic backslide — STEP-4 data shows ~two-thirds of lost weight returns within a year of discontinuation. Bridging matters.
Compounded semaglutide from $200/month at licensed 503A pharmacies keeps your therapy continuous while you fight the denial. Same molecule, custom dose, no insurance gatekeeping. Many patients stay on compounded after the appeal succeeds simply because the cash price beats the copay.
Under the Affordable Care Act, every insured American has the right to an external review by an Independent Review Organisation (IRO) after exhausting the internal appeal. The IRO is a third-party medical reviewer with no financial relationship to your insurer. Their decision is binding.
The most common reasons are: BMI below the plan threshold, plan formulary excludes weight-management drugs (very common for Wegovy/Zepbound), missing prior-authorisation paperwork, or step therapy requirements (plan wants you to fail older drugs first). Your denial letter will cite a specific code — start there. Some plans simply exclude all weight-loss drugs as a category, which is harder to overturn but still appealable on medical-necessity grounds.
Yes — and many patients do. Internal appeals (filed directly with the insurer) succeed roughly 30–40% of the time when accompanied by a strong Letter of Medical Necessity. External appeals (independent review organisations under ACA) succeed around 50% of the time. The key is a prescriber-authored LMN that documents BMI, comorbidities, prior attempts, and why this specific drug is medically necessary. Generic appeals without clinical detail almost always fail.
Standard internal appeals take 30–60 days. Expedited (urgent) appeals must be answered within 72 hours when delay would jeopardise health. External reviews add another 30–60 days. Total timeline from first denial to external decision: typically 60–120 days. During that window, compounded semaglutide or tirzepatide at cash prices ($200–400/mo) lets you continue therapy without losing the metabolic momentum you have built.
Roughly half of US employer-sponsored plans exclude obesity medications as a category. You can still appeal on medical-necessity grounds, especially if you have T2DM, prediabetes (A1c 5.7–6.4), PCOS, sleep apnea, or cardiovascular risk that benefits from GLP-1 therapy. You can also ask HR whether the plan covers Ozempic or Mounjaro for diabetes if your prescriber documents the diabetic indication. Otherwise, cash-pay compounded GLP-1 is the practical path until employers update formularies.
Yes, when dispensed by a state-licensed 503A compounding pharmacy under a valid prescription from a US-licensed prescriber for a specific patient. Compounded semaglutide is the same molecule as Ozempic and Wegovy. Look for pharmacies with documented sterility testing, USP <797> compliance, and state-board accreditation. Avoid "research peptide" websites that bypass prescribers — those are not legal medical channels and product quality is unverifiable.
Script Unlock surfaces cash prices for compounded GLP-1 at verified 503A pharmacies — keep your treatment continuous while paperwork moves.
Find cash prices